rotigaptide Report issue

Biologics Peptide Experimental
AACT DrugBank MeSH PubChem

Active Ingredient History

NOW
  • Now
Rotigaptide (ZP-123) is a drug under clinical investigation for the treatment of cardiac arrhythmias – specifically atrial fibrillation. It is a peptide analog that has been shown to increase gap junction intercellular conductance in cardiac muscle cells. Gap junctions are protein channels that are responsible for conducting electrical impulses between cells in the heart to maintain normal rhythm. Gap junction modulation is a promising and novel mechanism of action for the treatment of cardiovascular disorders. Its peptide sequence is Ac-D-Tyr-D-Pro-D-Hyp-Gly-D-Ala-Gly-NH2.   Wikipedia

Chemistry

  • SMILES: CC(=O)N[C@H](Cc1ccc(O)cc1)C(=O)N1CCC[C@@H]1C(=O)N1C[C@@H](O)C[C@@H]1C(=O)NCC(=O)N[C@H](C)C(=O)NCC(N)=O
  • InChIKey: GFJRASPBQLDRRY-TWTQBQJDSA-N
  • Mol. Mass: 617.66
  • ALogP: -3.39
  • ChEMBL Molecule:
    rotigaptide  
More Chemistry

Pharmacology

Alternative names

ac-d-tyr-d-pro-d-hyp-gly-d-ala-gly-nh2 | acetyl-tyrosyl-prolyl-hydroxyprolyl-glycyl-alanyl-glycinamide | ac-tyr-pro-hyp-gly-ala-gly-nh2 | gap-486 | rotigaptide | zp 123 | zp-123 | zp123 peptide

Organizations (5)

Research & Development (5)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (1)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (1)


 

Arrhythmias, Cardiac (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 4
  • # of Trial Organizations: 5

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue